SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is currently trending following a $75 million direct offering to an institutional investor, intended to fully fund its Phase 3 MASH trial, which has sparked mixed community reactions concerning dilution versus strategic positioning. This capital raise, coupled with a new 'Overweight' rating and $20 price target from Barclays and recent FDA Breakthrough Therapy Designation for pemvidutide, is fueling intense speculation around a potential short squeeze, partnership, or outright acquisition within the MASH and weight loss sector.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending significantly following reports that China has approved the import of its H200 AI chips, sparking widespread bullish sentiment. The community is actively discussing a potential substantial rally, with many anticipating the stock to break key resistance levels and reach new highs. This optimism is fueled by strong AI demand and upcoming big tech earnings, though some traders are wary of past volatility related to similar news.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is experiencing significant market attention as investors keenly await its earnings, propelled by expectations of massive bookings and optimistic analyst outlooks tied to the accelerating AI-driven semiconductor demand and robust capital expenditure plans from key customers. While many laud its crucial near-monopoly in advanced chipmaking, the community also debates its high valuation and the long-term implications of rising geopolitical tensions and reports of China's indigenous EUV technology development. The company remains a central figure in the broader chip equipment sector, reflecting confidence in the ongoing AI supercycle.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending with strong community sentiment, driven by its "culture-first" approach and a long-term, "bongterm" holding philosophy on the Solana blockchain. The community actively discusses the coin as a symbol for global cannabis culture, advocating for the plant's benefits in health and sustainability while positioning it as "like Bitcoin but way higher" due to its dedicated following and potential for future catalysts.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor interest following BlackRock's increased stake and the FDA's new flexibility on manufacturing requirements, which could expedite its BLA submission. The community is actively discussing the potential for significant partnerships or a buyout, driven by the company's promising oncology pipeline, particularly CAN-2409, amid a broader biopharma M&A surge to address looming patent cliffs. Many believe shorts are trapped due to low liquidity, signaling potential for upward price movement.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is experiencing a significant rally to new all-time highs, driven by growing community concerns over a weakening US dollar and increasing national debt, alongside broader geopolitical uncertainties. Investors are actively discussing a rotation into precious metals as a secure hedge, with many predicting substantial further gains while a minority cautiously eye a potential correction after the rapid ascent.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending due to a significant market reaction following a proposed lower-than-anticipated Medicare Advantage payment rate for 2027, rather than its recent earnings. This development has ignited fierce debate among investors, with many viewing the sell-off as an overreaction and a generational buying opportunity, while others anticipate continued pressure on UNH and the broader healthcare sector amid regulatory uncertainty and speculation of market manipulation.

Stride, Inc. is a technology-based educational company, which engages in the provision of proprietary and third-party curriculum, software systems and educational services. It also offers online curriculum and career services to middle and high school students, under the Destinations Career Academy brand name. The company was founded by Ronald J. Packard in 2000 and is headquartered in Reston, VA.

Stride Inc

Stride Inc. is trending strongly following an impressive earnings report that surpassed estimates with significant enrollment growth, particularly in Career Learning. The company also authorized a substantial stock repurchase program, sparking widespread community discussion about its undervalued position. Many are now discussing a potential short squeeze, given previous short interest and the company's strong performance in the expanding digital education space.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following its strategic acquisition of SkyWater Technology, a move seen by many as establishing the first vertically integrated, U.S.-based quantum computing platform. This development is sparking intense community discussion, with proponents highlighting potential national security contracts and an accelerated qubit roadmap, while some express concerns about shareholder dilution and the sector's current commercialization timeline. The integration aims to secure a domestic supply chain, positioning the company as a key player in the quantum supremacy race.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing a significant upward momentum, driven by continued tech sector strength, early positive mega-cap earnings, and a weakening dollar pushing it towards new all-time highs. The market community is sharply divided between fomo-driven bulls celebrating 

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Perkins Capital Management Inc. Invests $1.14 Million in Lucid Diagnostics Inc. $LUCD

Perkins Capital Management Inc. purchased a new stake in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) in the 3rd quarter, according to its most recent filing with the Securities...

What's Going On With PAVmed Shares Thursday?

PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diagnostics secured a contractread more...

Why Is PAVmed Stock Skyrocketing Wednesday?

PAVmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for its cancer prevention test.read more...

<ul class="summary-bullets"><li>The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing.</li><li>The agreement provides more than nine million enrolled veterans access to&nbsp;esophageal&nbsp;precancer testing.</li><li>Trading in PAVM shares was halted at 09:58 ET.</li></ul>Shares of PAVmed Inc. (PAVM) jumped more than 250% on Wednesday morning after its subsidiary, Lucid Diagnostics Inc. (LUCD), won a contract from the U.S. Department of Veterans Affairs (VA) to supply its EsoGuard Esophageal DNA Test for detecting esophageal precancer across the VA healthcare system.The agreement provides more than nine million enrolled veterans access to&nbsp;esophageal&nbsp;precancer testing.<a href="https://stocktwits.com/symbol/PAVM">PAVM</a> was among the top trending tickers on Stocktwits at the time of writing. <a href="https://stocktwits.com/symbol/LUCD">LUCD</a> shares jumped 23% to their highest levels since May 2025.<h2 class="st-heading-2">Contract Details</h2>The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing that aligns with the Medicare reimbursement rate set by the Centers for Medicare &amp; Medicaid Services. This structure allows VA hospitals and clinics nationwide to procure EsoGuard through a single, standardized framework.“The VA operates at significant clinical and operational scale, and selection by a healthcare system of this size reflects the strength of the clinical evidence supporting EsoGuard,” said Shaun O'Neil, President and Chief Operating Officer of Lucid Diagnostics.&nbsp;&nbsp;Lucid Diagnostics focuses on early cancer prevention diagnostics, particularly for patients with gastroesophageal reflux disease who face an elevated risk of developing esophageal precancer and cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for PAVM on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/PAVMED_jpg_a10dfa8673.webp" alt="PAVMED.jpg" width="925" height="96"><figcaption>PAVM's Sentiment Meter and Message Volumes at 10:20 a.m. ET on Jan. 21, 2026 | Source: Stocktwits</figcaption></figure>Sentiment for LUCD changed to ‘bullish’ from ‘neutral’ a day earlier, while message volumes were ‘extremely high’.One user believes the news has ‘real value’.<stembedurl>https://stocktwits.com/pow7904/message/642397455</stembedurl>PAVmed implemented a 1-for-30 reverse stock split on January 2.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gold-rises-to-record-highs-as-investors-seek-out-safe-haven-assets/cmUDMEjR4fK">Gold Jumps To All-Time Highs – Veteran trader Peter Brandt Says $8,000 An Ounce Is On The Cards</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PAVM Stock Shot Up Over 250% Today – What’s The Deal With The Department of Veterans Affairs?

PAVM Stock - The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

Equity

The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard

Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard PR Newswire NEW YORK, Jan. 21...

Lucid Diagnostics (NASDAQ:LUCD) Stock Price Up 0.9% - Here's Why

Lucid Diagnostics (NASDAQ:LUCD) Trading 0.9% Higher - Should You Buy...

PAVmed Announces Reverse Stock Split

PAVmed Announces Reverse Stock Split PAVmed Announces Reverse Stock Split PR Newswire NEW YORK, Dec. 30, 2025 NEW YORK, Dec. 30, 2025 /PRNewswire/ --PAVmed Inc.(NASDAQ: PAVM) ('PAVmed' or the...

Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) has been given an average rating of "Moderate Buy" by the five brokerages that are covering the company, MarketBeat reports. One equities...

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection Lucid Diagnostics Announces Positive Data from the Largest Reported...

Wednesday Sector Laggards: Diagnostics, Medical Instruments & Supplies

In trading on Wednesday, diagnostics shares were relative laggards, down on the day by about 0.4%. Helping drag down the group were shares of Nutex Health, off about 5.7% and shares of Lucid...

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

LUCD
Lucid Diagnostics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LUCD News

LUCDLucid Diagnostics Inc